臺灣博碩士論文加值系統

1948年的Framingham Heart Study是系統性心血管疾病評估風險的濫觴。1998年起以年齡、性別、血壓值、總膽固醇與高密度膽固醇、是否罹患糖尿病及吸菸與否，預測未來10年罹患冠狀動脈心臟疾病的可能性，逐漸修改迄今；然而需抽血檢驗數據方能進行風險評估，仍影響該工具的使用普及。頸動脈都普勒超音波是近年用來評估頸動脈硬化的有利工具，過去已有許多研究利用頸動脈都普勒超音波評估腦血管疾病風險，但對於心血管疾病的相關性有待更多探索。本研究以頸動脈都普勒超音波獲得之血液流速數據，比較既有的量化性風險評估工具，以彰顯兩者之相關性。

The risk assessment for cardiovascular disease began in 1948 with the Framingham Heart Study. Before the study, we knew almost nothing about the epidemiology for arteriosclerotic or hypertensive cardiovascular disease. Gender, age, blood pressure, total or high-density lipoprotein cholesterol, suffered from diabetes mellitus or not, and current smoking status were used to predict the 10-year heart disease risk, and which have been gradually revised so far. However, blood test data are required for risk assessment which still affects the use of tools widespread. Non-invasive carotid ultrasonography is a useful tool for evaluating carotid vascular atherosclerosis in recent years. Many studies have used carotid ultrasonography to evaluate the risk of cerebrovascular disease, but the correlation between cardiovascular disease needs to be further studied. In this study, blood velocity data obtained from non-invasive carotid ultrasonography were compared with existing cardiovascular risk assessment tools to confirm the correlation between them.

Content
中文摘要 I
Abstract II
Chapter 1 Introduction 1
1.1 Research background information 1
1.1.1 Framingham Heart Study for coronary heart disease (10-year CHD risk) 2
1.1.2 Framingham Heart Study for cardiovascular disease (10-year CVD risk) 3
1.1.3 Atherosclerotic Cardiovascular Disease Risk Estimator 4
1.1.4 ASCVD Risk Estimator Plus 4
1.1.5 SCORE2 risk prediction algorithms 5
1.1.6 WHO/ISH CVD risk 5
1.1.7 Carotid Doppler ultrasonography 6
1.2 Research Purpose 9
Chapter 2 Material and Method 11
2.1 Participants 11
2.2 Definition of Variables 11
2.3 Carotid ultrasonography measurement 13
2.4 Data Analysis 14
Chapter 3 Research results 16
3.1 Univariate analysis 16
3.2 Ordinal logistic regression (OLR) analysis 26
Chapter 4 Discussion and conclusions 33
4.1 Conclusions 36
4.2 Limitations of the study 36
4.3 Suggestions for Future Research 37
Reference 38
Appendix A 45

1.Geneva S. WHO reveals leading causes of death and disability worldwide: 2000-2019: World Health Organization (WHO); 2020 [updated 9 December 2020. Available from: https://www.who.int/news/item/09-12-2020-who-reveals-leading-causes-of-death-and-disability-worldwide-2000-2019.
2.World health statistics 2009 [Internet]. Geneva: World Health Organization; 2009 [Available from: www.who.int/gho/publications/world_health_statistics/EN_WHS09_Full.pdf.
3.2020 Cause of Death Statistics Taiwan: Department of Statistics, Ministry if Health and Welfare, Taiwan; 2021 [updated 1 October, 2021. Available from: https://www.mohw.gov.tw/dl-72005-6ae2355c-e69d-47a3-9b4b-e87b6bf68eae.html.
4.HEARTS: Technical package for cardiovascular disease management in primary health care 2017 [Internet]. Geneva: World Health Organization; 2016 [Available from: www.who.int/cardiovascular_diseases/hearts/Hearts_package.pdf.
5.Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. The Lancet. 2014;383(9921):999-1008.
6.Dawber TR, Moore FE, Mann GV. II. Coronary Heart Disease in the Framingham Study. American Journal of Public Health and the Nations Health. 1957;47(4_Pt_2):4-24.
7.Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J. Factors of Risk in the Development of Coronary Heart Disease—Six-Year Follow-up Experience. Annals of Internal Medicine. 1961;55(1):33-50.
8.Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22(3):312-8.
9.Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation. 1997;96(1):44-9.
10.Kannel WB, D'Agostino RB, Silbershatz H, Belanger AJ, Wilson PW, Levy D. Profile for estimating risk of heart failure. Arch Intern Med. 1999;159(11):1197-204.
11.Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-47.
12.Merry AH, Boer JM, Schouten LJ, Ambergen T, Steyerberg EW, Feskens EJ, et al. Risk prediction of incident coronary heart disease in The Netherlands: re-estimation and improvement of the SCORE risk function. Eur J Prev Cardiol. 2012;19(4):840-8.
13.Marques-Vidal P, Rodondi N, Bochud M, Chiolero A, Pécoud A, Hayoz D, et al. Predictive accuracy of original and recalibrated Framingham risk score in the Swiss population. Int J Cardiol. 2009;133(3):346-53.
14.Brindle P, Emberson J, Lampe F, Walker M, Whincup P, Fahey T, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. Bmj. 2003;327(7426):1267.
15.Barzi F, Patel A, Gu D, Sritara P, Lam TH, Rodgers A, et al. Cardiovascular risk prediction tools for populations in Asia. J Epidemiol Community Health. 2007;61(2):115-21.
16.Liu J, Hong Y, D'Agostino RB, Sr., Wu Z, Wang W, Sun J, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. Jama. 2004;291(21):2591-9.
17.Nishimura K, Okamura T, Watanabe M, Nakai M, Takegami M, Higashiyama A, et al. Predicting Coronary Heart Disease Using Risk Factor Categories for a Japanese Urban Population, and Comparison with the Framingham Risk Score: The Suita Study. J Atheroscler Thromb. 2016;23(9):1138-9.
18.Chia YC, Gray SY, Ching SM, Lim HM, Chinna K. Validation of the Framingham general cardiovascular risk score in a multiethnic Asian population: a retrospective cohort study. BMJ Open. 2015;5(5):e007324.
19.Chien KL, Hsu HC, Su TC, Chang WT, Chen PC, Sung FC, et al. Constructing a point-based prediction model for the risk of coronary artery disease in a Chinese community: a report from a cohort study in Taiwan. Int J Cardiol. 2012;157(2):263-8.
20.Zhang Y, Miao H, Chia YC, Buranakitjaroen P, Siddique S, Shin J, et al. Cardiovascular risk assessment tools in Asia. J Clin Hypertens (Greenwich). 2022;24(4):369-77.
21.Chang H-Y, Fang H-L, Huang C-Y, Hung L-S, Chien K-L, Pan W-H. Estimating the Calibrating Coefficient of the Framingham Score to Predict Risk of Coronary Heart Disease in the Taiwanese Population. International Journal of Gerontology. 2019;13(1):64-8.
22.D'Agostino RB, Sr., Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-53.
23.Goff DC, Jr., Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Sr., Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2935-59.
24.Dawber TR, Kannel WB, Lyell LP. An approach to longitudinal studies in a community: the Framingham Study. Ann N Y Acad Sci. 1963;107:539-56.
25.Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol. 1979;110(3):281-90.
26.Friedman GD, Cutter GR, Donahue RP, Hughes GH, Hulley SB, Jacobs DR, Jr., et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol. 1988;41(11):1105-16.
27.Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1(3):263-76.
28.The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol. 1989;129(4):687-702.
29.Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-e646.
30.Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285-e350.
31.Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2018;71(19):e127-e248.
32.Lloyd-Jones DM, Huffman MD, Karmali KN, Sanghavi DM, Wright JS, Pelser C, et al. Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2017;69(12):1617-36.
33.SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439-54.
34.Scoutt LM, Gunabushanam G. Carotid Ultrasound. Radiol Clin North Am. 2019;57(3):501-18.
35.Sacco RL. Clinical practice. Extracranial carotid stenosis. N Engl J Med. 2001;345(15):1113-8.
36.Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003;108(14):1664-72.
37.Spagnoli LG, Mauriello A, Sangiorgi G, Fratoni S, Bonanno E, Schwartz RS, et al. Extracranial thrombotically active carotid plaque as a risk factor for ischemic stroke. Jama. 2004;292(15):1845-52.
38.Tonnessen BH, Money SR. Commentary on: Redgrave JNE, Lovett JK, Gallagher PJ, et al. Histological assessment of 526 symptomatic carotid plaques in relation to the nature and timing of ischemic symptoms: the Oxford Plaque Study. Circulation. 2006; 113:2320-2328. Perspect Vasc Surg Endovasc Ther. 2007;19(2):194-5.
39.Mineva PP, Manchev IC, Hadjiev DI. Prevalence and outcome of asymptomatic carotid stenosis: a population-based ultrasonographic study. Eur J Neurol. 2002;9(4):383-8.
40.Mannami T, Konishi M, Baba S, Nishi N, Terao A. Prevalence of asymptomatic carotid atherosclerotic lesions detected by high-resolution ultrasonography and its relation to cardiovascular risk factors in the general population of a Japanese city: the Suita study. Stroke. 1997;28(3):518-25.
41.Su TC, Jeng JS, Chien KL, Sung FC, Hsu HC, Lee YT. Hypertension status is the major determinant of carotid atherosclerosis: a community-based study in Taiwan. Stroke. 2001;32(10):2265-71.
42.Nadareishvili ZG, Rothwell PM, Beletsky V, Pagniello A, Norris JW. Long-term risk of stroke and other vascular events in patients with asymptomatic carotid artery stenosis. Arch Neurol. 2002;59(7):1162-6.
43.Inzitari D, Eliasziw M, Gates P, Sharpe BL, Chan RK, Meldrum HE, et al. The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med. 2000;342(23):1693-700.
44.AIUM Practice Parameter for the Performance of an Ultrasound Examination of the Extracranial Cerebrovascular System. J Ultrasound Med. 2016;35(9):1-11.
45.Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008;21(2):93-111; quiz 89-90.
46.Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation. 1997;96(5):1432-7.
47.O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK, Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340(1):14-22.
48.Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002;106(16):2055-60.
49.Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001;357(9256):577-81.
50.Lonn EM, Gerstein HC, Sheridan P, Smith S, Diaz R, Mohan V, et al. Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). J Am Coll Cardiol. 2009;53(22):2028-35.
51.Crouse JR, 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. Jama. 2007;297(12):1344-53.
52.Hosomi N, Mizushige K, Ohyama H, Takahashi T, Kitadai M, Hatanaka Y, et al. Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke. 2001;32(7):1539-45.
53.Gimbrone MA, Jr., García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ Res. 2016;118(4):620-36.
54.Chiu JJ, Chien S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev. 2011;91(1):327-87.
55.Baratchi S, Khoshmanesh K, Woodman OL, Potocnik S, Peter K, McIntyre P. Molecular Sensors of Blood Flow in Endothelial Cells. Trends Mol Med. 2017;23(9):850-68.
56.(IAC) IAC. IAC Standards and Guidelines for Vascular Testing Accreditation 2021 [Available from: https://intersocietal.org/wp-content/uploads/2021/11/IACVascularTestingStandards2021.pdf.
57.Grant EG, Benson CB, Moneta GL, Alexandrov AV, Baker JD, Bluth EI, et al. Carotid artery stenosis: grayscale and Doppler ultrasound diagnosis--Society of Radiologists in Ultrasound consensus conference. Ultrasound Q. 2003;19(4):190-8.
58.Frauchiger B, Schmid HP, Roedel C, Moosmann P, Staub D. Comparison of carotid arterial resistive indices with intima-media thickness as sonographic markers of atherosclerosis. Stroke. 2001;32(4):836-41.
59.Tanimoto S, Ikari Y, Tanabe K, Yachi S, Nakajima H, Nakayama T, et al. Prevalence of carotid artery stenosis in patients with coronary artery disease in Japanese population. Stroke. 2005;36(10):2094-8.
60.House AK, Bell R, House J, Mastaglia F, Kumar A, D'Antuono M. Asymptomatic carotid artery stenosis associated with peripheral vascular disease: a prospective study. Cardiovasc Surg. 1999;7(1):44-9.
61.Cinà CS, Safar HA, Maggisano R, Bailey R, Clase CM. Prevalence and progression of internal carotid artery stenosis in patients with peripheral arterial occlusive disease. J Vasc Surg. 2002;36(1):75-82.
62.Grundy SM, Stone NJ. 2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline. Ann Intern Med. 2019;170(11):779-83.
63.Hsieh HC, Hsu JC, Lu CY. 10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database. BMJ Open. 2017;7(5):e014150.
64.Nutrition and Health Survey in Taiwan (NAHSIT, 2017-2020): Health Promotion Administration. Ministry of Health and Welfare, Taiwan; 2022 [updated 5 June 2022. 9 May 2022:[Available from: https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=3999&pid=15562.
65.Chuang SY, Bai CH, Cheng HM, Chen JR, Yeh WT, Hsu PF, et al. Common carotid artery end-diastolic velocity is independently associated with future cardiovascular events. Eur J Prev Cardiol. 2016;23(2):116-24.
66.Zhang H, Liu M, Ren T, Wang X, Liu D, Xu M, et al. Associations between Carotid Artery Plaque Score, Carotid Hemodynamics and Coronary Heart Disease. Int J Environ Res Public Health. 2015;12(11):14275-84.
67.Chuang SY, Cheng HM, Mitchell GF, Sung SH, Chen CH, Pan WH, et al. Carotid Flow Velocities and Blood Pressures Are Independently Associated With Cognitive Function. Am J Hypertens. 2019;32(3):289-97.
68.Westholm C, Johnson J, Sahlen A, Winter R, Jernberg T. Peak systolic velocity using color-coded tissue Doppler imaging, a strong and independent predictor of outcome in acute coronary syndrome patients. Cardiovasc Ultrasound. 2013;11:9.
69.König CS, Atherton M, Cavazzuti M, Gomm C, Ramachandran S. The association of peak systolic velocity in the carotid artery with coronary heart disease: A study based on portable ultrasound. Proc Inst Mech Eng H. 2021;235(6):663-75.
70.Kim ES, Marycz DM, Archinal D, Gornik HL, Shishehbor MH, Bartholomew JR. Presence of external carotid artery plaque independently predicts mortality in patients without internal carotid artery atherosclerosis. Vasc Med. 2014;19(5):351-5.
71.Rutgers DR, Klijn CJ, Kappelle LJ, van Huffelen AC, van der Grond J. A longitudinal study of collateral flow patterns in the circle of Willis and the ophthalmic artery in patients with a symptomatic internal carotid artery occlusion. Stroke. 2000;31(8):1913-20.
72.Hu HH, Wang S, Chern CM, Yeh HH, Sheng WY, Lo YK. Clinical significance of the ophthalmic artery in carotid artery disease. Acta Neurol Scand. 1995;92(3):242-6.
73.Costa VP, Kuzniec S, Molnar LJ, Cerri GG, Puech-Leão P, Carvalho CA. Collateral blood supply through the ophthalmic artery: a steal phenomenon analyzed by color Doppler imaging. Ophthalmology. 1998;105(4):689-93.
74.Chuang SY, Bai CH, Chen JR, Yeh WT, Chen HJ, Chiu HC, et al. Common carotid end-diastolic velocity and intima-media thickness jointly predict ischemic stroke in Taiwan. Stroke. 2011;42(5):1338-44.
75.Bellinazzi VR, Cipolli JA, Pimenta MV, Guimarães PV, Pio-Magalhães JA, Coelho-Filho OR, et al. Carotid flow velocity/diameter ratio is a predictor of cardiovascular events in hypertensive patients. J Hypertens. 2015;33(10):2054-60.